NDLI: The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.

Please wait, while we are loading the content...

Year: 2017 Volume: 75

Year: 2016 Volume: 74

Year: 2015 Volume: 73

Year: 2014 Volume: 72

Year: 2013 Volume: 71

Year: 2012 Volume: 70

Year: 2011 Volume: 69

Year: 2010 Volume: 68

Year: 2009 Volume: 67

Year: 2009 Volume: 67 Issue: 12

Year: 2009 Volume: 67 Issue: 11

Year: 2009 Volume: 67 Issue: 11 Supplementary

Year: 2009 Volume: 67 Issue: 10

Year: 2009 Volume: 67 Issue: 9

Year: 2009 Volume: 67 Issue: 9 Supplementary

Year: 2009 Volume: 67 Issue: 8

Year: 2009 Volume: 67 Issue: 7

Year: 2009 Volume: 67 Issue: 6

Year: 2009 Volume: 67 Issue: 5

Year: 2009 Volume: 67 Issue: 5 Supplementary

Comprehensive review of bisphosphonate therapy: implications for the oral and maxillofacial surgery patient.

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development.

Bisphosphonates--role in cancer therapies.

Alternative indications for bisphosphonate therapy.

Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.

Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.

Bisphosphonates--what the dentist needs to know: practical considerations.

The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry.

Imaging findings in bisphosphonate-related osteonecrosis of jaws.

The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.

Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws.

Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws.

Year: 2009 Volume: 67 Issue: 4

Year: 2009 Volume: 67 Issue: 3

Year: 2009 Volume: 67 Issue: 2

Year: 2009 Volume: 67 Issue: 1

Year: 2008 Volume: 66

Year: 2007 Volume: 65

Year: 2006 Volume: 64

Year: 2005 Volume: 63

The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Carlson, Eric R. Basile, John D.
Description	Country affiliation: United States Author Affiliation: Carlson ER ( Department of Oral and Maxillofacial Surgery, University of Tennessee Medical Center and University of Tennessee Cancer Institute, Knoxville, TN 37920, USA. ecarlson@mc.utmck.edu)
Abstract	PURPOSE: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a poorly understood pathologic entity from the standpoints of its nomenclature, frequency, pathogenesis, and best method of treatment. In particular, numerous recommendations have been made for treatment involving nonsurgical therapy. It is the purpose of this article to specifically examine the success of resection of the necrotic bone in the mandible and maxilla in these patients. PATIENTS AND METHODS: We identified 103 sites of BRONJ in 82 patients. Of these sites of osteonecrosis, 32 were in the maxilla and 71 were in the mandible. Of the patients, 30 were taking an oral bisphosphonate medication whereas 52 were taking a parenteral bisphosphonate medication. Resection was performed in 95 sites of osteonecrosis in 74 patients, whereas 8 sites diagnosed in 8 patients were not resected. A total of 27 sites of BRONJ were resected in patients treated with oral bisphosphonates, and 68 sites of BRONJ were resected in patients treated with parenteral bisphosphonates. RESULTS: Of the 95 resected sites, 87 (91.6%) healed in an acceptable fashion with resolution of disease. Of 27 resected sites in patients taking an oral bisphosphonate medication, 26 (96.3%) healed satisfactorily, with refractory disease developing in 1 site. Of 68 resected sites in patients taking a parenteral bisphosphonate medication, 61 (89.7%) healed satisfactorily, with refractory disease developing in 7 sites. All 29 patients (100%) undergoing resection of the maxilla related to either an oral or parenteral bisphosphonate healed acceptably. The 8 patients who had the development of refractory disease did so with a range of 7 to 250 days postoperatively (mean, 73 days). Of the 8 sites of refractory disease, 6 developed after a marginal resection of the mandible for BRONJ. Three sites of new primary disease developed in 2 patients postoperatively. Both patients were taking a parenteral bisphosphonate medication. Histologic examination of the resected specimens identified malignant disease in 4 specimens in 3 patients. CONCLUSION: Resection of BRONJ permits acceptable healing in patients taking an oral bisphosphonate medication. In addition, resection of BRONJ of the maxilla in patients taking an oral or parenteral bisphosphonate medication follows a predictable course with regard to healing. Resection of BRONJ of the mandible in patients taking a parenteral bisphosphonate medication follows a variable postoperative course, although a high degree of success is realized. Surgeons should consider resection of necrotic bone of the maxilla and mandible that develops in patients taking bisphosphonate medications. In addition, refractory disease can be successfully managed with a more aggressive resection, specifically, a segmental resection of the mandible after a marginal resection of the mandible where refractory disease developed.
File Format	HTM / HTML
ISSN	02782391
Issue Number	5 Suppl
Volume Number	67
e-ISSN	15315053
Journal	Journal of Oral and Maxillofacial Surgery
Language	English
Publisher	Elsevier
Publisher Date	2009-05-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Medicine__semicolon__otorhinolaryngology__semicolon__surgery Bone Density Conservation Agents Adverse Effects Diphosphonates Jaw Diseases Chemically Induced Surgery Oral Surgical Procedures Osteonecrosis Administration, Oral Administration & Dosage Female Humans Injections, Intravenous Jaw Male Prospective Studies Reoperation Treatment Outcome Journal Article
Content Type	Text
Resource Type	Article
Subject	Oral Surgery Otorhinolaryngology Surgery

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in